Skip to main content
. Author manuscript; available in PMC: 2021 Mar 31.
Published in final edited form as: Science. 2020 Feb 7;367(6478):652–660. doi: 10.1126/science.aay0542

Fig. 4. Both an AMPK agonist and a caspase-6 inhibitor therapeutically improve liver damage.

Fig. 4.

(A to I) C57BL/6J mice were fed CD-HFD for 6 weeks, followed by intraperitoneal injection of 25 mg/kg A-769662 or vehicle daily for 2 weeks while fed continuous CD-HFD. (A) Liver sections stained TUNEL (red) and DAPI (blue). Scale bar, 50 μm. (B) Quantification of TUNEL-positive nuclei per field in (A); n = 7 mice. [(C) to (E)] Serum ALT (C), AST (D), and ALP (E); n = 7 mice. (F) H&E and Sirius red staining of liver sections. Scale bar, 100 μm. (G) Quantification of liver fibrosis area (percent of total area) in (F); n = 7 mice. (H) Liver hydroxyproline; n = 8 mice. (I) Expression of Tgfb, Timp1, Col1a1, Col3a1, Pdgfa, Pdgfb, Pdgfra, and Ddr2 in livers; n = 8 mice. *P < 0.05, Student’s unpaired t test. (J to L) Flox and LAKO mice were fed CD-HFD for 6 weeks, followed by intraperitoneal injection of 5 mg/kg VEID or vehicle every other day for 2 weeks while continuously feeding. (J) Liver sections stained TUNEL (red) and DAPI (blue). Scale bar, 50 μm. (K) Quantification of TUNEL-positive nuclei per field in (J); n = 5 to 6 mice. Mean ± SEM; *P < 0.05, two-way ANOVA.